Shilpa Medicare Ltd., a research-led global integrated pharmaceutical company, today announced another first time in the world Oral Thin Film formulation, a pediatric dose Paracetamol Oral Thin Film, under the Brand name Molshil.

Shilpa received approval for Molshil oral thin films  after sufficiently complying bioequivalence requirements.

Shilpa's Paracetamol oral thin films  are patent protected and are first of this kind in the world.

The new presentation of Paracetamol from Shilpa will have benefits of easy administration, excellent palatability and overcome disadvantages of presently available pediatric formulations like dose variation, sedimentation or poor suspendability, presence of alcohol, messy and crystallized bottles in usage, fragile glass bottles etc.

Shilpa has manufacturing facilities for paracetamol at both Hyderabad and Bangalore.

Shilpa has launched Paracetamol Oral Thin Films as 60 mg and 120 mg strengths in Orange Flavor.